* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Leukaemia Section t(3;5)(q25;q34) Atlas of Genetics and Cytogenetics
Genetic code wikipedia , lookup
Genomic imprinting wikipedia , lookup
Genome evolution wikipedia , lookup
Gene expression programming wikipedia , lookup
Vectors in gene therapy wikipedia , lookup
Minimal genome wikipedia , lookup
History of genetic engineering wikipedia , lookup
Neocentromere wikipedia , lookup
Site-specific recombinase technology wikipedia , lookup
Nutriepigenomics wikipedia , lookup
Epigenetics of neurodegenerative diseases wikipedia , lookup
Gene nomenclature wikipedia , lookup
Protein moonlighting wikipedia , lookup
X-inactivation wikipedia , lookup
Gene expression profiling wikipedia , lookup
Designer baby wikipedia , lookup
Polycomb Group Proteins and Cancer wikipedia , lookup
Epigenetics of human development wikipedia , lookup
Genome (book) wikipedia , lookup
Helitron (biology) wikipedia , lookup
Point mutation wikipedia , lookup
Microevolution wikipedia , lookup
Therapeutic gene modulation wikipedia , lookup
Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL AT INIST-CNRS Leukaemia Section Short Communication t(3;5)(q25;q34) Jean-Loup Huret Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France Published in Atlas Database: August 1997 Online version is available at: http://AtlasGeneticsOncology.org/Anomalies/t0305.html DOI: 10.4267/2042/32030 This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence. © 1997 Atlas of Genetics and Cytogenetics in Oncology and Haematology Clinics and pathology Results of the chromosomal anomaly Disease ANLL; may be preceded by MDS; BC-CML Phenotype / cell stem origin M2, M4, M6 (although a rare subtype) ANLL; trilineage involvement. Epidemiology Med. age: 35 yrs; balanced sex ratio. Prognosis CR: 8/12, but median survival is less than 1 yr. Hybrid gene Description 5' NPM-3' MLF1 on der(5). Fusion protein Expression localisation 54 kDa with the 175 N-term amino acids from NPM; localization: nucleus, mainly in the nucleolus. To be noted Cytogenetics Specific comments: this translocation share some (but not all) common features with t(1;3)(p36;q21), inv(3)(q21q26)..., although the genes involved on chromosome 3 are different. Cytogenetics, morphological Location of breakpoints is difficult to ascertain. Additional anomalies Most often none; +8. References Genes involved and Proteins De Braekeleer M, Vekemans M. A t(3;5) in blastic phase of a Philadelphia chromosome-negative chronic myeloid leukemia. Cancer Genet Cytogenet 1989 Feb; 37(2):163-8. (Review). Grigg AP, Gascoyne RD, Phillips GL, Horsman DE. Clinical, haematological and cytogenetic features in 24 patients with structural rearrangements of the Q arm of chromosome 3. Br J Haematol 1993; 83:158-65. Yoneda-Kato N, Look AT, Kirstein MN, Valentine MB, Raimondi SC, Cohen KJ, Carroll AJ, Morris SW. The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene 1996; 12:265-275. MLF1 Location: 3q25 Protein 31 kDa; do not contain known functional motifs; widely expressed; cytoplasmic localisation. NPM1 Location: 5q34 Protein Nuclear localisation; binds to single and double strand nucleic acids; phosphoprotein that may transport ribonucleoproteins; may also have a role in DNA replication. Atlas Genet Cytogenet Oncol Haematol. 1997; 1(1) This article should be referenced as such: Huret JL. t(3;5)(q25;q34). Atlas Genet Cytogenet Oncol Haematol.1997;1(1):18. 18